Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 46.88 percent increase over losses of $(0.32) per share from the same period last year.